The 10-second takeaway
For the quarter ended Dec. 31 (Q4), MAKO Surgical beat expectations on revenue and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.
Margins improved across the board.
MAKO Surgical reported revenue of $32.9 million. The six analysts polled by S&P Capital IQ expected to see a top line of $30.2 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $14.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.14. The seven earnings estimates compiled by S&P Capital IQ forecast -$0.14 per share. GAAP EPS were -$0.14 for Q4 versus -$0.26 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.1%, 960 basis points better than the prior-year quarter. Operating margin was -17.1%, 4,970 basis points better than the prior-year quarter. Net margin was -17.0%, 4,940 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $24.6 million. On the bottom line, the average EPS estimate is -$0.18.
Next year's average estimate for revenue is $130.8 million. The average EPS estimate is -$0.43.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 716 members out of 744 rating the stock outperform, and 28 members rating it underperform. Among 201 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 194 give MAKO Surgical a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is outperform, with an average price target of $33.75.
The healthcare investing landscape is littered with also-rans and a few major winners. Is MAKO Surgical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add MAKO Surgical to My Watchlist.